NCT04947033View on ClinicalTrials.gov

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

TJ210001 Injection

The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.

Trial Locations (1)

310000

RECRUITING

Shanghai East Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

I-Mab Biopharma US Limited

INDUSTRY